• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

    8/20/24 8:42:04 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBIO alert in real time by email
    SC 13D/A 1 ef20034416_sc13da.htm SC 13D/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13D
    (Amendment No. 3)*

    BridgeBio Pharma, Inc.
    (Name of Issuer)

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

    10806X102
    (CUSIP Number)

    Andrew Genser
    General Counsel
    600 Washington Boulevard, Floor 11
    Stamford, Connecticut 06901
    (212) 672-7050
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    August 16, 2024
    (Date of Event Which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box: ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 2 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Investors LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    25,120,991 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    13.4%  (see Item 5) (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

     
    1.
    All share percentage calculations in this Amendment No. 3 to the Schedule 13D are based on 188,032,738 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the “Issuer”) outstanding as of July 25, 2024, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the “Commission”) on August 1, 2024.


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 3 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Performance LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    631,167 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    631,167 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    631,167 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.3% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 4 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Equities Master Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    631,167 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    631,167 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    631,167 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.3% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 5 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Long Fund GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    251,204 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    251,204 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    251,204 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.1% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 6 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Long Fund Master Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    251,204 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    251,204 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    251,204 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.1% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 7 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Parent GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,238,620 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    12.9%  (see Item 5) (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 8 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,238,620 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    12.9% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 9 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Portfolio GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,238,620 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    12.9% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 10 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,238,620 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    12.9% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 11 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    O. Andreas Halvorsen
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Norway
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    25,120,991 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    13.4% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 12 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    David C. Ott
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    25,120,991 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    13.4% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 13 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Rose S. Shabet
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    25,120,991 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    13.4% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 14 of 15
    EXPLANATORY NOTE

    Pursuant to Rule 13d-2 of the Securities Exchange Act of 1934, as amended, this Amendment No. 3 to the Schedule 13D (“Amendment No. 3”) amends certain items of the Schedule 13D filed with the Commission on July 8, 2019, as amended and supplemented by Amendment No. 1 filed with the Commission on July 19, 2023 and Amendment No. 2 filed with the Commission on November 22, 2023 (collectively, the “Schedule 13D”) relating to the Common Stock, par value $0.001 per share (the “Common Stock”) of BridgeBio Pharma, Inc., a Delaware corporation (the “Issuer”). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.

    Item 4.
    Purpose of Transaction

    Item 4 of the Schedule 13D is hereby amended and supplemented as follows:

    On August 16, 2024, the Issuer, on the recommendation of a special committee of independent and disinterested directors of the Issuer, entered into a transaction agreement (the “Transaction Agreement”) providing for the formation and funding by certain third party investors (the “Investors”) of GondolaBio, LLC, a Delaware limited liability company (“GondolaBio”), as a joint venture for the purpose of researching, developing, manufacturing and commercializing pharmaceutical products, including those contributed to GondolaBio by the Issuer (the “Transaction”). The Investors providing financing to GondolaBio consist of an investor syndicate, including Opportunities Fund and Viking Global Opportunities Drawdown (Aggregator) LP (“VGOD”). The general partner of VGOD is Viking Global Opportunities Drawdown Portfolio GP LLC, whose sole member is Viking Global Opportunities Drawdown GP LLC, whose sole member is Opportunities Parent. The Transaction was consummated (the “Closing”) on the date of signing the Transaction Agreement.

    Pursuant to the Transaction Agreement, the Issuer contributed to GondolaBio certain early-stage clinical and pre-clinical stage programs in the areas of Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex. The Investors have committed $300 million of tranched financing to GondolaBio. The initial interest in GondolaBio of each of Opportunities Fund and VGOD is approximately 12% and 6%, respectively, and is expected to increase as additional tranches of capital contributions are funded.

    Also on August 16, 2024, each of the Investors, including Opportunities Fund and VGOD, became a party to the Amended and Restated Limited Liability Company Agreement of GondolaBio (the “LLC Agreement”). The LLC Agreement sets forth, among other things, the economic and governance rights of the members of GondolaBio, including governance rights, economic preferences, privileges, restrictions and obligations of the members.

    The foregoing descriptions of the Transaction Agreement and the LLC Agreement do not purport to be complete and are qualified in their entirety by reference to the full text thereof, copies of which are filed as Exhibit 99.4 and Exhibit 99.5, respectively, to this Amendment No. 3 and are incorporated herein by reference.

    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    Item 6 of the Schedule 13D is hereby amended and supplemented as follows:

    The information set forth or included in Item 4 of this Amendment No. 3 is incorporated herein by reference.

    Item 7.
    Materials to be Filed as Exhibits

    Item 7 of the Schedule 13D is hereby amended and supplemented as follows:

    Exhibit No.
    Description
    99.4
    Transaction Agreement, dated as of August 16, 2024, by and among the Issuer, the Investors and GondolaBio (incorporated by reference to Exhibit 10.1 to the Issuer’s current report on Form 8-K dated August 20, 2024).
    99.5
    Amended and Restated Limited Liability Company Agreement of GondolaBio, dated as of August 16, 2024 (incorporated by reference to Exhibit 10.2 to the Issuer’s current report on Form 8-K dated August 20, 2024).


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 15 of 15
    SIGNATURES
     
    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated: August 20, 2024     

        

    By:
    /s/ Scott M. Hendler

    Name:
    Scott M. Hendler on behalf of O. Andreas Halvorsen (1)

    By:
    /s/ Scott M. Hendler

    Name:
    Scott M. Hendler on behalf of David C. Ott (2)

    By:
    /s/ Scott M. Hendler

    Name:
    Scott M. Hendler on behalf of Rose S. Shabet (3)

    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737).

    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).



    Get the next $BBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BBIO

    DatePrice TargetRatingAnalyst
    3/31/2025$50.00Buy
    Redburn Atlantic
    10/16/2024Sector Outperform
    Scotiabank
    10/3/2024Perform
    Oppenheimer
    9/4/2024$46.00Overweight
    Piper Sandler
    3/21/2024$45.00Outperform
    Raymond James
    1/31/2024$37.00Market Perform
    BMO Capital Markets
    12/8/2023$58.00Overweight
    Wells Fargo
    12/8/2023Overweight
    Wells Fargo
    More analyst ratings

    $BBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Valantine Hannah bought $44,476 worth of shares (3,433 units at $12.96) (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      2/13/24 4:00:10 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

      PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference 2025 in Las Vegas, NV on Wednesday, May 14 at 2:20 pm PT. To access the live webcast of BridgeBio's presentation, please visit the "Events" page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event. About BridgeBio Pha

      5/7/25 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

      - $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study for hypochondroplasia Phase 2 trial fully enrolled significantly ahead of schedule. The first participant was also dosed in the Phase 2 interventional study - Proof-of-principle study of encaleret, an oral calcium-sensing receptor antagonist, in hypoparathyroidism resulted in 78% of N=9 study participants achieving concomitant normal blood and urine calcium within 5 days. The Company intends to advance development to enable registration in chronic hypoparathyroidism - The Company ended the qu

      4/29/25 4:01:00 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

      - The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date - In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo- A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30- A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30 - Acoramidis is the first and only approved ATTR-CM treatment in the U.S., EU, UK and Japan that all have a label specifying near-complete stabilization (≥90%) - Relat

      4/28/25 5:00:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BBIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

      SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

      11/6/24 5:04:05 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

      SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

      9/17/24 6:41:54 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

      SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

      8/20/24 8:42:04 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

      Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

      11/25/24 8:41:11 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Financials

    Live finance-specific insights

    See more
    • BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

      PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market closes on Tuesday, April 29, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events" page within the Investors section of the BridgeBio website at https://investor.bridgebio.com/news-and-events/event-calendar. A replay of the webcast will be a

      4/22/25 7:30:37 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

      - As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR stabilizer (≥90%) was approved by the FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients on November 22, 2024 - Acoramidis was approved as BEYONTTRA™ in the EU on February 10, 2025, achieving a $75 million milestone payment and ongoing royalties in a tiered structure beginning in the low-thirties percent on sales in the EU - Acoramidis demonstrated a 59% hazard reduction on the composite endpoint of all-cause mortality and first

      2/20/25 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

      PALO ALTO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024, on February 20, 2025. As part of the announcement, the Company will also share updates on Attruby's commercialization progress and its late-stage clinical pipeline. The Company will begin hosting earnings calls with the Q1 earnings release, expected in late April or early May, as outlined in its JPM presentation. About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. (BridgeBio) is a new ty

      2/13/25 4:01:00 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on BridgeBio Pharma with a new price target

      Redburn Atlantic initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $50.00

      3/31/25 8:12:33 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on BridgeBio Pharma

      Scotiabank initiated coverage of BridgeBio Pharma with a rating of Sector Outperform

      10/16/24 8:38:45 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on BridgeBio Pharma

      Oppenheimer initiated coverage of BridgeBio Pharma with a rating of Perform

      10/3/24 7:23:31 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

      PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D. In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business success at BridgeBio. He will lead cross-functional activities to develop a centralized ope

      7/23/24 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

      The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood FundThis capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it progresses multiple assets into the clinic to treat patients with a wide variety of RAS and PI3Kα pathway malignancies PALO ALTO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commerci

      5/2/24 7:00:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors

      PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health's efforts to promote diversity, equity, and inclusion in biomedical research. Dr. Valantine currently serves as a professor of medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. Dr. Valantine was elected to the National Academy of Medicine in 2020 for her research in organ transplantation

      10/25/21 7:30:00 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Apuli Maricel sold $39,509 worth of shares (1,026 units at $38.51), decreasing direct ownership by 0.69% to 147,639 units (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      5/6/25 4:45:19 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lo Andrew sold $3,849,900 worth of shares (100,000 units at $38.50) (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      5/6/25 4:42:23 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Kumar Neil sold $2,558,025 worth of shares (75,000 units at $34.11) (SEC Form 4)

      4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

      4/24/25 4:28:13 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBIO
    SEC Filings

    See more
    • SEC Form 144 filed by BridgeBio Pharma Inc.

      144 - BridgeBio Pharma, Inc. (0001743881) (Subject)

      5/2/25 4:36:36 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by BridgeBio Pharma Inc.

      DEFA14A - BridgeBio Pharma, Inc. (0001743881) (Filer)

      4/30/25 4:13:02 PM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by BridgeBio Pharma Inc.

      DEF 14A - BridgeBio Pharma, Inc. (0001743881) (Filer)

      4/30/25 6:01:50 AM ET
      $BBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care